Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Use of progestogen therapy.

R D Gambrell

    American Journal of Obstetrics and Gynecology
    |May 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Adding progestogen to estrogen therapy significantly reduces endometrial cancer risk in postmenopausal women. This combination also lowered breast cancer incidence compared to estrogen alone or no treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Moderate dosage estrogen-androgen therapy improves continuation rates in postmenopausal women: impact of the WHI reports.

    Climacteric : the journal of the International Menopause Society·2006
    Same author

    Physicians should provide moral leadership to their communities: Presidential address.

    American journal of obstetrics and gynecology·2000
    Same author

    Estrogen replacement therapy in women with previous breast cancer.

    American journal of obstetrics and gynecology·1999
    Same author

    Strategies to reduce the incidence of endometrial cancer in postmenopausal women.

    American journal of obstetrics and gynecology·1997
    Same author

    Hormone replacement therapy and breast cancer risk.

    South African journal of surgery. Suid-Afrikaanse tydskrif vir chirurgie·1996
    Same author

    Hormone replacement therapy and breast cancer risk.

    Archives of family medicine·1996
    Same journal

    Association of Surgical Approach with Oncologic Outcomes in Low-Risk Cervical Cancer.

    American journal of obstetrics and gynecology·2026
    Same journal

    Trends in Infertility Treatments by Race, Ethnicity, Socioeconomic Status, and Region in U.S. Birth Certificates from Live Births: 2011-2022.

    American journal of obstetrics and gynecology·2026
    Same journal

    Likelihood ratios enhance clinical interpretation of metagenomic prediction of early-onset neonatal sepsis in preterm premature rupture of membranes (Letter-to-the-Editor).

    American journal of obstetrics and gynecology·2026
    Same journal

    Taking risk stratification in preterm premature rupture of membranes to the bedside (Reply to Letter-to-the-Editor).

    American journal of obstetrics and gynecology·2026
    Same journal

    Gestational Age at Full-Term Delivery and Long-Term Offspring Morbidity in Low-Risk Pregnancies: A Population-Based Cohort Study.

    American journal of obstetrics and gynecology·2026
    Same journal

    Trajectories of childbirth-related posttraumatic stress symptoms after a vaginal delivery: a multicenter prospective study.

    American journal of obstetrics and gynecology·2026
    See all related articles

    Area of Science:

    • Gynecology
    • Oncology
    • Endocrinology

    Background:

    • Estrogen therapy for postmenopausal women linked to increased endometrial cancer risk.
    • Progestogen addition to estrogen may mitigate this risk.
    • Some postmenopausal women may not require estrogen replacement therapy.

    Purpose of the Study:

    • To identify postmenopausal women at high risk for endometrial cancer.
    • To evaluate the impact of estrogen and progestogen therapy on cancer incidence.

    Main Methods:

    • Utilized the progestogen challenge test to identify at-risk women.
    • Retrospective analysis of cancer incidence from 1975-1983 at Wilford Hall U.S. Air Force Medical Center.
    • Compared cancer rates among unopposed estrogen users, estrogen-progestogen users, and untreated women.

    Related Experiment Videos

    Main Results:

    • Endometrial cancer incidence was lowest in estrogen-progestogen users (49.0/100,000) compared to unopposed estrogen (390.6/100,000) and untreated women (245.5/100,000).
    • Breast cancer incidence was significantly lower in estrogen-progestogen users (66.8/100,000) than in untreated women (343.5/100,000).
    • Cancer rates in estrogen-progestogen users were lower than expected national averages.

    Conclusions:

    • Progestogen challenge test aids in identifying women at high risk for endometrial cancer.
    • Adding progestogens to estrogen replacement therapy is recommended for all postmenopausal women, regardless of hysterectomy status.
    • Estrogen-progestogen therapy demonstrates a protective effect against both endometrial and breast cancer.